Equities Analysts Offer Predictions for Vigil Neuroscience, Inc.'s Q2 2024 Earnings (NASDAQ:VIGL)

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2024 earnings per share (EPS) estimates for Vigil Neuroscience in a research report issued to clients and investors on Wednesday, March 27th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.58) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $24.00 target price on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.51) per share. HC Wainwright also issued estimates for Vigil Neuroscience's Q4 2024 earnings at ($0.58) EPS, FY2024 earnings at ($2.32) EPS, FY2025 earnings at ($2.35) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at $0.44 EPS and FY2028 earnings at $0.99 EPS.

Separately, Morgan Stanley lowered Vigil Neuroscience from an "equal weight" rating to an "underweight" rating and lowered their price objective for the stock from $13.00 to $4.00 in a research report on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Vigil Neuroscience has an average rating of "Moderate Buy" and a consensus target price of $17.40.

Vigil Neuroscience Trading Up 6.6 %

Vigil Neuroscience stock traded up $0.21 during mid-day trading on Friday, hitting $3.41. The company's stock had a trading volume of 79,539 shares, compared to its average volume of 112,542. The firm has a market capitalization of $125.78 million, a PE ratio of -1.60 and a beta of 1.80. Vigil Neuroscience has a 1 year low of $2.53 and a 1 year high of $11.11. The stock's fifty day moving average is $3.09 and its two-hundred day moving average is $4.30.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada acquired a new position in Vigil Neuroscience during the second quarter worth $33,000. California State Teachers Retirement System acquired a new position in Vigil Neuroscience during the second quarter worth $50,000. Wells Fargo & Company MN lifted its stake in Vigil Neuroscience by 6,988.4% during the second quarter. Wells Fargo & Company MN now owns 6,096 shares of the company's stock worth $57,000 after purchasing an additional 6,010 shares in the last quarter. Strs Ohio acquired a new position in Vigil Neuroscience during the fourth quarter worth $27,000. Finally, Morgan Stanley lifted its stake in Vigil Neuroscience by 6,893.8% during the fourth quarter. Morgan Stanley now owns 9,092 shares of the company's stock worth $114,000 after purchasing an additional 8,962 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.